BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InteRNA Technologies Joins European SIROCCO Consortium to Study RNA Silencing


11/7/2008 10:16:01 AM

BILTHOVEN, The Netherlands, November 6 /PRNewswire/ -- InteRNA Technologies B.V. is pleased to announce that it has joined the SIROCCO research consortium consisting of 25 world-class laboratories and companies from 10 countries for studying how RNA silencing could be used to treat life-threatening diseases, including cancer.

SIROCCO stands for "Silencing RNAs: organisers and coordinators of complexity in eukaryotic organisms". InteRNA will join for the remaining 2.5 years of this EUR 11.8 million funded four-year Integrated Project under the EU Sixth Framework Programme.

InteRNA's contribution will focus on discovery, data mining and development of diagnostic miRNA and other small RNA profiles through next-generation sequencing, in combination with InteRNA's proprietary small RNA bioinformatics pipeline, miR-Intess(TM), of diverse patient sample sets provided by consortium members and other sources.

"Pleased as we were by the invitation to become a partner in the SIROCCO consortium, we are very excited that we now can participate in this unique small RNA consortium as it will further support the progression of our discovery and development programs," said Roel Schaapveld, Chief Operating Officer of InteRNA Technologies.

About InteRNA Technologies B.V.

InteRNA Technologies B.V. actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The company's primary focus is to unravel the role of its proprietary miRNAs in cancer.

InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and has established close relationships with the leading miRNA research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD.

See for more information http://www.interna-technologies.com.

For further information on the SIROCCO project, please visit http://www.sirocco-project.eu.

CONTACT: Contact: Roel Q.J. Schaapveld, PhD, MBA, COO, InteRNA
Technologies B.V., Phone: +31-30-229-6095, E-mail:
schaapveld@interna-technologies.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES